Mammoth Biosciences Stock

mammoth.bioBioTechFounded: 2017Funding to Date: $257.38MM

Mammoth Biosciences is a biotechnology company that, through the discovery and development of novel CRISPR systems, the is enabling the full potential of its platform to improve lives by reading and writing the code of life.

Enterprise Value (based on primary financings)

Register for Details

For more details on financing and valuation for Mammoth Biosciences, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

Trevor Martin Ph.D
Co-Founder & Chief Executive Officer
Ted Tisch
Chief Operating Officer
Janice Chen Ph.D
Co-Founder & Chief Technology Officer
Lucas Harrington
Co-Founder & Chief Scientific Officer
Peter Nell Ph.D
Chief Business Officer and Head of Therapeutics
Jennifer Doudna Ph.D
Co-Founder & Chairman of Scientific Advisory Board

Board Members

Jennifer Doudna Ph.D
Mammoth Biosciences
Ursheet Parikh
Mayfield Fund

Other companies like Mammoth Biosciences in the BioTech sector

Sector
Last Round Est. Valuation
$4.89B
Sector
Last Round Est. Valuation
$872.62MM
Sector
Last Round Est. Valuation
$486.63MM
Sector
Last Round Est. Valuation
$186.12MM
Sector
Last Round Est. Valuation
$50.4MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$185MM
Sector
Last Round Est. Valuation
$289.42MM

News

San Francisco-based Mammoth Biosciences has closed on a $150 million Series D led by Redmile Group, which now values the CRISPR biotech company at $1 billion, making it a new addition to the Crunchbase Unicorn Board.
CRISPR tech startup Mammoth Biosciences is among the companies that revealed backing from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) program on Friday. Mammoth received a contract to scale up its CRISPR-based SARS-CoV-2 diagnostic test in order to help address …
California-based Mammoth Biosciences has signed a powerful partner for its development of a CRISPR-based test for COVID-19, which would aim to delivery accurate, fast results using a handheld, disposable testing platform. Mammoth Biosciences will be using its DETECTR platform to develop the test, w…